Echo Browning
Family · Central City, KYNPI 1871016287
Payments from drug & device makers
Across 94 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Indivior Inc.$181
- USWM, LLC$147
- AbbVie$140
- Otsuka America Pharmaceutical, Inc.$131
- Gilead$123
- Alkermes, Inc.$111
- plus $730 from 15 others
What the payments were for
- Food & beverage$1,563100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Indivior Inc. | 10 | $181 |
| USWM, LLC | 9 | $147 |
| AbbVie | 8 | $140 |
| Otsuka America Pharmaceutical, Inc. | 7 | $131 |
| Gilead | 6 | $123 |
| Alkermes, Inc. | 7 | $111 |
| Corium, LLC | 6 | $97 |
| Idorsia Pharmaceuticals US Inc | 5 | $69 |
| Axsome Therapeutics, Inc. | 4 | $65 |
| Vanda Pharmaceuticals Inc. | 3 | $64 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $57 |
| Antares Pharma, Inc. | 4 | $56 |
| Lilly USA, LLC | 3 | $52 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $50 |
| Pfizer | 3 | $46 |
| Braeburn Inc. | 3 | $42 |
| Lundbeck LLC | 2 | $37 |
| Novo Nordisk | 2 | $33 |
| Almatica Pharma LLC | 2 | $28 |
| Corcept Therapeutics | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
How this compares
$1,563 in reported general payments places this provider in the 70th percentile of 4,374 family providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 12 | $293,656 |
| OzempicSemaglutide | 60 | $66,147 |
| JardianceEmpagliflozin | 44 | $34,247 |
| LinzessLinaclotide | 34 | $23,356 |
| XyostedTestosterone Enanthate | 31 | $18,696 |
| TrulicityDulaglutide | 11 | $10,814 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $9,896 |
| EntrestoSacubitril/Valsartan | 12 | $7,721 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 73 | $2,345 |
| Gabapentin | 209 | $2,138 |
| Ondansetron OdtOndansetron | 84 | $2,030 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $1,690 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,227 |
| Diclofenac Sodium-MisoprostolDiclofenac Sodium/Misoprostol | 11 | $1,170 |
| Amiodarone Hcl | 16 | $711 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa | $123 | $293,65612 claims |
| Novo NordiskOzempic | $33 | $66,14760 claims |
| AbbVieLinzess | $140 | $23,35634 claims |
| Antares Pharma, Inc.Xyosted | $56 | $18,69631 claims |
| Lilly USA, LLCTrulicity | $52 | $10,81411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,374 family providers in Kentucky.
Other family in Central City
- Bonnie HillLouisa$372K
- Ashley SnellenElizabethtown$190K
- Smita RanjanLouisville$92K
- Elizabeth SaltLexington$89K
- Tracey GaslinLouisville$79K
- Kassandra GreenLouisville$69K
- Danielle RevertLouisville$65K
- Lora BrownMonticellow$61K
- Shelley WaldmanLouisville$59K
- Vicki ChapmanMount Vernon$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.